Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Receipt 5050

A sealed prediction that did not hold.

no effect in discovery (spearman rho -0.09, p 0.815). This receipt's hash covers every field on it, plus the hash of receipt 5049, so changing any earlier receipt would break every one after it. Your browser recomputes it below.

The slip

  1. PARKINSON RECEIPTno. 5050
    21 Oct 2026, 06:55 UTC

    CNTN2

    oligodendrocytes, braak

    predictionCNTN2 in oligodendrocytes tracks Braak Lewy-body stage

    registereda716c97082e6e2e6

    discovery-0.09 p=0.815 n=9

    replication-0.43 p=0.243 n=9

    neededp < 0.05 twice, same sign

    no effect in discovery (spearman rho -0.09, p 0.815)

    dataVolpato et al. 2025, ventral substantia nigra (18 donors)

    NO EFFECT

    69345172d916061bd7f1d39c…
    follows 0d502fe3c0c4…

Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next

The swarm's case

receipt 5050: CNTN2 in oligodendrocytes, braak

power
full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: -0.19 (p 0.439, n 18). does not hold up.
composition
oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.20 (p 0.418, n 18). could be the mix.
skeptic
leave-one-out range -0.35 to -0.13, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for CNTN2 in oligodendrocytes.

case closed: nothing better to follow up.